Literature DB >> 27303043

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.

Sylvia Mahara1, Puay Leng Lee2, Min Feng2, Vinay Tergaonkar3, Wee Joo Chng4, Qiang Yu5.   

Abstract

Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer.

Entities:  

Keywords:  EZH2; FOXM1; PRC2; breast cancer; hypoxia

Mesh:

Substances:

Year:  2016        PMID: 27303043      PMCID: PMC4932959          DOI: 10.1073/pnas.1602079113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

2.  Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.

Authors:  Jiro Kikuchi; Daisuke Koyama; Taeko Wada; Tohru Izumi; Peter O Hofgaard; Bjarne Bogen; Yusuke Furukawa
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

3.  EZH2 couples pancreatic regeneration to neoplastic progression.

Authors:  Jon Mallen-St Clair; Rengin Soydaner-Azeloglu; Kyoung Eun Lee; Laura Taylor; Alexandra Livanos; Yuliya Pylayeva-Gupta; George Miller; Raphaël Margueron; Danny Reinberg; Dafna Bar-Sagi
Journal:  Genes Dev       Date:  2012-03-01       Impact factor: 11.361

4.  Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension.

Authors:  B H Jiang; J Z Zheng; S W Leung; R Roe; G L Semenza
Journal:  J Biol Chem       Date:  1997-08-01       Impact factor: 5.157

5.  The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Authors:  Woo Kyun Bae; Kyung Hyun Yoo; Ji Shin Lee; Young Kim; Ik-Joo Chung; Min Ho Park; Jung Han Yoon; Priscilla A Furth; Lothar Hennighausen
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

6.  FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.

Authors:  Aamir Ahmad; Zhiwei Wang; Dejuan Kong; Shadan Ali; Yiwei Li; Sanjeev Banerjee; Raza Ali; Fazlul H Sarkar
Journal:  Breast Cancer Res Treat       Date:  2009-10-08       Impact factor: 4.872

7.  EZH2 expands breast stem cells through activation of NOTCH1 signaling.

Authors:  Maria E Gonzalez; Heather M Moore; Xin Li; Kathy A Toy; Wei Huang; Michael S Sabel; Kelley M Kidwell; Celina G Kleer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 8.  The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles.

Authors:  Inken Wierstra
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Authors:  Sakari Vanharanta; Weiping Shu; Fabienne Brenet; A Ari Hakimi; Adriana Heguy; Agnes Viale; Victor E Reuter; James J-D Hsieh; Joseph M Scandura; Joan Massagué
Journal:  Nat Med       Date:  2012-12-09       Impact factor: 53.440

View more
  26 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  Molecular switch of EZH2 in hypoxia.

Authors:  Sylvia Mahara; Wee Joo Chng; Qiang Yu
Journal:  Cell Cycle       Date:  2016-07-26       Impact factor: 4.534

3.  DZNep inhibits Hif-1α and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.

Authors:  Rui Huang; Xiu Jin; Yongying Gao; Hongmei Yuan; Fei Wang; Xiangmei Cao
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

4.  IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.

Authors:  Li-Teng Ong; Wee Chyan Lee; Shijun Ma; Gokce Oguz; Zhitong Niu; Yi Bao; Mubaraka Yusuf; Puay Leng Lee; Jian Yuan Goh; Panpan Wang; Kylie Su Mei Yong; Qingfeng Chen; Wenyu Wang; Adaikalavan Ramasamy; Dave S B Hoon; Henrik J Ditzel; Ern Yu Tan; Soo Chin Lee; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

5.  Hypoxia induced-disruption of lncRNA TUG1/PRC2 interaction impairs human trophoblast invasion through epigenetically activating Nodal/ALK7 signalling.

Authors:  Mengsi Hu; Yao Wang; Yanping Meng; Jinxiu Hu; Jiao Qiao; Junhui Zhen; Decai Liang; Minghua Fan
Journal:  J Cell Mol Med       Date:  2022-06-21       Impact factor: 5.295

6.  Splice variants of cytosolic polyadenylation element-binding protein 2 (CPEB2) differentially regulate pathways linked to cancer metastasis.

Authors:  James T DeLigio; Grace Lin; Charles E Chalfant; Margaret A Park
Journal:  J Biol Chem       Date:  2017-09-13       Impact factor: 5.157

7.  EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.

Authors:  Xiaowen Guan; Houliang Deng; Un Lam Choi; Zhengfeng Li; Yiqi Yang; Jianming Zeng; Yunze Liu; Xuanjun Zhang; Gang Li
Journal:  Oncogene       Date:  2020-10-02       Impact factor: 9.867

Review 8.  Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.

Authors:  Talha Anwar; Maria E Gonzalez; Celina G Kleer
Journal:  Am J Pathol       Date:  2021-02-06       Impact factor: 4.307

9.  Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.

Authors:  Harish N Vasudevan; Steve E Braunstein; Joanna J Phillips; Melike Pekmezci; Bryan A Tomlin; Ashley Wu; Gerald F Reis; Stephen T Magill; Jie Zhang; Felix Y Feng; Theodore Nicholaides; Susan M Chang; Penny K Sneed; Michael W McDermott; Mitchel S Berger; Arie Perry; David R Raleigh
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

10.  A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia.

Authors:  Xingwen Wang; Yudong Wang; Li Li; Xuting Xue; Hui Xie; Huaxing Shi; Ying Hu
Journal:  Oncogene       Date:  2019-11-29       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.